U.S. Markets open in 3 hrs 46 mins
  • S&P Futures

    3,902.00
    +4.25 (+0.11%)
     
  • Dow Futures

    31,241.00
    +39.00 (+0.12%)
     
  • Nasdaq Futures

    11,838.00
    -40.25 (-0.34%)
     
  • Russell 2000 Futures

    1,771.50
    -3.40 (-0.19%)
     
  • Crude Oil

    110.35
    +0.46 (+0.42%)
     
  • Gold

    1,845.10
    +3.90 (+0.21%)
     
  • Silver

    21.87
    -0.03 (-0.13%)
     
  • EUR/USD

    1.0562
    -0.0026 (-0.2429%)
     
  • 10-Yr Bond

    2.7870
    -0.0680 (-2.38%)
     
  • Vix

    29.43
    +0.08 (+0.27%)
     
  • GBP/USD

    1.2495
    +0.0020 (+0.1587%)
     
  • USD/JPY

    127.8500
    +0.0560 (+0.0438%)
     
  • BTC-USD

    30,406.89
    +497.82 (+1.66%)
     
  • CMC Crypto 200

    650.34
    -23.03 (-3.42%)
     
  • FTSE 100

    7,389.98
    +87.24 (+1.19%)
     
  • Nikkei 225

    26,739.03
    +336.19 (+1.27%)
     

Puma Biotech's Neratinib Fails To Extend Overall Survival In Brain Cancer Trial

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Puma Biotechnology Inc (NASDAQ: PBYI) announced interim data from the neratinib arm of Phase 2 INSIGhT Trial in newly diagnosed unmethylated glioblastoma with IDH R132H mutation-negative.

  • In the intent-to-treat population, progression-free survival (PFS) was not significantly longer with neratinib (median 6.0 months) versus the control arm (median 4.7 months).

  • Also, there was no significant improvement in overall survival (OS) between neratinib (median 13.8 months) vs. the control arm (14.7 months).

  • For patients with activation of the EGFR pathway, PFS was significantly longer with neratinib (median 6.3 months) vs. the control arm (4.6 months).

  • However, there was no significant improvement in OS between neratinib (median 14.4 months) vs. the control arm (15.3 months).

  • Neratinib was generally well-tolerated in the trial, and toxicities for neratinib were similar to those previously described.

  • For the 81 patients treated with neratinib, there were 6 cases (7.4%) of grade 3 diarrhea and no cases of grade 4 diarrhea. No new toxicity signals were identified in the trial.

  • Related: Puma Biotech's Nerlynx Wins Canadian Approval In HER2-Positive Metastatic Breast Cancer.

  • Price Action: PBYI shares closed at $3.42 on Friday.

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.